Dr. Lance Gordon, director for Neglected Infectious Diseases in the Global Health Program, leads the effort to reduce the burden of selected infectious diseases on the world’s poorest people through effective control, elimination, or eradication. The NID strategy encompasses a set of 17 disease initiatives selected based on disease burden and the opportunity to achieve transformational change through partnerships with others.
Dr. Gordon has over 30 years of experience in the vaccine and pharmaceutical industry, contributing to the development of vaccines and drugs. He was the inventor and developer of the first bacterial conjugate vaccine to receive FDA and European approval. He received his Ph.D. in Biomedical Science, Immunology from the University of Connecticut and completed his postdoctoral fellowship in the Division of Allergy and Immunology, Washington University Medical School, St. Louis. Dr. Gordon previously served as CEO and a member of the Board of Directors of three publically traded vaccine companies, VaxGen, OraVax and North American Vaccines.